Sethuraman Natarajan's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed May 4, 2026
- Accession no.
- 0001873394-26-000003
- Filed
- May 4, 2026
- Trade date
- May 4, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $398.7K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sethuraman NatarajanCIK 0001873394 | Officer (President, Research & Develop.) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | Common Stock | SSaleDisposed | −25,907 | $15.39 | −$398,708.73 | 216,317 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.